Trials / Completed
CompletedNCT03054194
Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Study E2730-A001-001 is a first-in-human, sequential ascending single dose, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of a single oral dose of E2730 in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E2730 | capsules |
| DRUG | Placebo | capsules |
Timeline
- Start date
- 2017-01-31
- Primary completion
- 2017-03-02
- Completion
- 2017-03-02
- First posted
- 2017-02-15
- Last updated
- 2018-09-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03054194. Inclusion in this directory is not an endorsement.